Search
for
Sort by
Research 601–630 of 1000+
- More than 50 long-term effects of COVID-19: a systematic review and meta-analysis
- Mucocutaneous reactions to chemotherapy
- Severe cutaneous adverse reactions to drugs
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
- Comorbidities in alopecia areata: A systematic review and meta-analysis
- Biocomposite nanofiber matrices to support ECM remodeling by human dermal progenitors and enhanced wound closure
- Mood and Sexual Function in Polycystic Ovary Syndrome
- Red ginseng monograph
- Review of quality of life studies in women with alopecia
- HAIR AND SYSTEMATIC DISEASE
- Cutaneous and Mucosal Manifestations Associated with Celiac Disease
- Dermatologic Manifestations of Human Immunodeficiency Virus Infection
- Drug-induced acne
- 5α-Reduced glucocorticoids: a story of natural selection
- The safety of 52 weeks of oral DHEA therapy for postmenopausal women
- Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study
- The changing patterns of hair density and thickness in South Korean women with hair loss: clinical office-based phototrichogram analysis
- Post‐COVID-19 syndrome: assessment of short- and long-term post-recovery symptoms in recovered cases in Saudi Arabia
- Evaluation of Oral Minoxidil in the Treatment of Alopecia Areata
- Trichotillomania: Clinical Aspects and Treatment Strategies *
- Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
- Ashy Dermatosis
- Hair and nail involvement in lupus erythematosus
- Kawasaki disease: an update
- REVIEW OF SO-CALLED ASEPTIC NEUTROPHILIC DERMATOSES
- Polycystic Ovarian Syndrome in Adolescents
- Liquid nitrogen cryotherapy vs. Betamethasone lotion in the management of Alopecia areata
- Skin diseases in Turkish renal transplant recipients
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III